New number of shares and votes in Moberg Pharma AB (publ)
STOCKHOLM, June 30th, 2022, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 100,859,335 due to the completion of the previously announced rights issue, the previously announced directed issue to certain guarantors in the rights issue and the previously announced issue of class C shares, which subsequently have been repurchased and converted to common shares, intended to ensure fulfilment of commitments under incentive programmes.
During June 2022, the total number of shares and votes in the company has increased by 54,178,212, corresponding to 54,178,212 votes, whereof 52,516,260 common shares through the registration of the rights issue, 536,952 common shares through the directed issue to the guarantors in the rights issue and 1,125,000 shares as a result of an issue of class C shares. The newly issued class C shares have been repurchased and, by virtue of the conversion clause in the articles of association, converted to common shares, and are held by the company to secure its commitments under incentive programmes.
As per June 30th, 2022, the last trading day in June, the total number of shares in Moberg Pharma AB (publ) amounts to 100,859,335. All shares are common shares. The total number of votes are 100,859,335. At the date of this press release, the Company holds 2,589,746 own common shares.
For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, telephone: +46 76 - 805 82 88, e-mail: mark.beveridge@mobergpharma.se
About this information
The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on June 30th, 2022, at 8:00 am CEST.
About Moberg Pharma, www.mobergpharma.se
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the Company's goal is to receive its first market approval and launch MOB-015 in 2023. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).
Tags: